

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		08978633
	Filing Date		1997-11-25
	First Named Inventor		Rabbani, E.
	Art Unit		
	Examiner Name		Angell, J.
	Attorney Docket Number		Enz-53-D1

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS						Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	08978633
		Filing Date	1997-11-25
		First Named Inventor	Rabbani, E.
		Art Unit	
		Examiner Name	Angell, J.
		Attorney Docket Number	Enz-53-D1

	1	Pat. App. No. 08574443 (Attny. Dkt. No. Enz-53) Non-Final Rejection 1999-02-19	<input type="checkbox"/>
	2	Pat. App. No. 08574443 (Attny. Dkt. No. Enz-53) Non-Final Rejection 1996-11-25	<input type="checkbox"/>
	3	WYATT et al. "Replication-deficient Vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells" Virology 210: 202-205. 1995	<input type="checkbox"/>
	4	MANSKY et al. "Lower In Vivo Mutation Rate of Human Immunodeficiency Virus Type 1 than That Predicted from the Fidelity of Purified Reverse Transcriptase" J. Virol. 69: 5087-5094. 1995	<input type="checkbox"/>
	5	JUNKER et al. "Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy" Gene Therapy 2: 639-645. 1995	<input type="checkbox"/>
	6	WOLFE et al. "The effect of sodium ion concentration on intrastrand base-pairing in single-stranded DNA" Nucleic Acids Res. 22: 3147-3150. 1994	<input type="checkbox"/>
	7	BUCHHOLZ et al. "The Carboxy-terminal domain of Sendai virus nucleocapsid protein is involved in complex formation between phosphoprotein and nucleocapsid-like particles" Virology 204: 770-776. 1994	<input type="checkbox"/>
	8	HO et al. "Expression in animal cells of the 5-HT1A receptor by a vaccinia virus vector system" FEBS 278: 229-233. 1992	<input type="checkbox"/>
	9	PATTNAIK et al. "Cells that express all five proteins of vesicular stomatitis virus from cloned cDNAs support replication, assembly, and budding of defective interfering particles" Proc. Natl. Acad. Sci. USA 88: 1379-1383. 1991	<input type="checkbox"/>
	10	KARSCHIN et al., "K + channel expression in primary cell cultures mediated by vaccinia virus" FEBS 278: 229-233. 1991	<input type="checkbox"/>
	11	SULLENGER et al. "Expression of Chimeric tRNA-Driven Antisense Transcripts Renders NIH 3T3 Cells Highly Resistant to Moloney Murine Leukemia Virus Replication" Mol. Cell. Biol. 10: 6512-6523. 1990	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		08978633
	Filing Date		1997-11-25
	First Named Inventor		Rabbani, E.
	Art Unit		
	Examiner Name		Angell, J.
	Attorney Docket Number		Enz-53-D1

	12	MOSS et al. "Product Review: New Mammalian Expression Vectors" Nature 348: 91-92. 1990	<input type="checkbox"/>
	13	ELROY-STEIN "Cytoplasmic expression system based on constitutive synthesis of bacteriophage T7 RNA polymerase in mammalian cells" Proc. Natl. Acad. Sci. USA 87: 6743-6747. 1990	<input type="checkbox"/>
	14	BUONOCORE et al. "Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum" Nature 345: 625-628. 1990	<input type="checkbox"/>
	15	BRAKEL et al. US Patent Application (Serial No. 07446235, filed 1989-12-04)	<input type="checkbox"/>
	16	EDLIND et al. "Intrastrand Base Pairing in Single-Stranded Deoxyribonucleic Acid from CoIE1-Derived Plasmid pCR1" J. Bacteriol. 145: 1436-1441. 1981	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.